董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles McDermott | 男 | Director | 48 | 10.87万美元 | 未持股 | 2020-03-26 |
| Bala S. Manian | 男 | Director | 74 | 11.07万美元 | 未持股 | 2020-03-26 |
| Stephen Connelly | 男 | Director,Chief Scientific Officer | 38 | 未披露 | 未持股 | 2020-03-26 |
| Mark Pruzanski | 男 | Director | 52 | 未披露 | 未持股 | 2020-03-26 |
| Daniel M. Bradbury | 男 | Director, Executive Chairman | 58 | 120.34万美元 | 未持股 | 2020-03-26 |
| Mark Pruzanski | 男 | Director | 52 | 9.72万美元 | 未持股 | 2020-03-26 |
| Martha J. Demski | 女 | Director | 67 | 11.32万美元 | 未持股 | 2020-03-26 |
| Bruce D. Steel | 男 | Director,President and Chief Executive Officer | 53 | 135.89万美元 | 未持股 | 2020-03-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason A. Keyes | 男 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2020-03-26 |
| Stephen Connelly | 男 | Director,Chief Scientific Officer | 38 | 未披露 | 未持股 | 2020-03-26 |
| Krishna R. Polu | -- | Executive Vice President, Research and Development | 47 | 未披露 | 未持股 | 2020-03-26 |
| Christine Zedelmayer | 女 | Senior Vice President, Chief Operating Officer | 50 | 未披露 | 未持股 | 2020-03-26 |
| Krishna R. Polu | 男 | Executive Vice President, Research and Development | 47 | 150.81万美元 | 未持股 | 2020-03-26 |
| Bruce D. Steel | 男 | Director,President and Chief Executive Officer | 53 | 135.89万美元 | 未持股 | 2020-03-26 |
董事简历
中英对照 | 中文 | 英文- Charles McDermott
-
Charles McDermott自2018年9月起担任董事会成员。McDermott先生自2019年3月起担任Primmune Therapeutics，Inc.（一家私人持有的生物技术公司）的董事长，总裁兼首席执行官。McDermott先生于2017年9月至2018年5月担任Impact Biomedicines，Inc.（一家私人持有的生物技术公司）的总裁兼首席商务官。在此之前，麦克德莫特先生于2015年6月至2017年8月担任上市生物制药公司Kala制药有限公司的总裁兼首席商务官。此前，他曾于2014年10月至2015年6月担任Kala的临时总裁兼首席商务官，并于2013年6月至2014年10月担任Kala业务发展执行Vice President。在加入Kala公司之前，McDermott先生曾于2005年4月至2013年5月在Allergan plc公司（一家上市的全球制药公司）担任业务发展、眼部护理和药物输送的董事和Vice President。加入Allergan之前，McDermott从2001年1月到2005年3月在Decode Genetics，Inc.（现为DGI Resolutions，Inc.，一家私营生物制药公司）担任多个业务开发职位。在Decode Genetics之前，McDermott先生是Agouron Pharmaceuticals，Inc.血管生成药理学小组的研究科学家。McDermott先生目前担任欧米茄基金（Omega Funds）的顾问，这是一家创建和投资生命科学公司的投资公司。McDermott先生拥有圣地亚哥大学（University of San Diego）的工商管理硕士学位，加州大学圣巴巴拉分校（University of California at Santa Barbara）的分子，细胞和发育生物学硕士学位，California University of Santa Cruz生物化学和分子生物学学士学位以及University of California San Diego Extension临床试验设计和管理证书。
Charles McDermott has served as a member of our Board since September 2018. Mr. McDermott has served as Chairman, President and Chief Executive Officer of Primmune Therapeutics, Inc., a privately-held biotechnology company, since March 2019. From September 2017 to May 2018 Mr. McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately-held biotechnology company. Prior to that, Mr. McDermott served as President and Chief Business Officer of Kala Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from June 2015 to August 2017. Previously, he served as Interim President and Chief Business Officer of Kala from October 2014 to June 2015 and as Executive Vice President of Business Development of Kala from June 2013 to October 2014. Prior to joining Kala, Mr. McDermott served first as Director and then Vice President of Business Development, Eye Care and Drug Delivery at Allergan plc, a publicly-held global pharmaceutical company, where he worked from April 2005 to May 2013. Prior to joining Allergan, Mr. McDermott held a variety of business development positions at deCODE Genetics, Inc. now DGI Resolutions, Inc., a privately-held biopharmaceutical company, from January 2001 to March 2005. Prior to deCODE Genetics, Mr. McDermott was a research scientist in the angiogenesis pharmacology group at Agouron Pharmaceuticals, Inc. Mr. McDermott currently serves as an Advisor to Omega Funds, an investment firm that creates and invests in life sciences companies. Mr. McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension. - Charles McDermott自2018年9月起担任董事会成员。McDermott先生自2019年3月起担任Primmune Therapeutics，Inc.（一家私人持有的生物技术公司）的董事长，总裁兼首席执行官。McDermott先生于2017年9月至2018年5月担任Impact Biomedicines，Inc.（一家私人持有的生物技术公司）的总裁兼首席商务官。在此之前，麦克德莫特先生于2015年6月至2017年8月担任上市生物制药公司Kala制药有限公司的总裁兼首席商务官。此前，他曾于2014年10月至2015年6月担任Kala的临时总裁兼首席商务官，并于2013年6月至2014年10月担任Kala业务发展执行Vice President。在加入Kala公司之前，McDermott先生曾于2005年4月至2013年5月在Allergan plc公司（一家上市的全球制药公司）担任业务发展、眼部护理和药物输送的董事和Vice President。加入Allergan之前，McDermott从2001年1月到2005年3月在Decode Genetics，Inc.（现为DGI Resolutions，Inc.，一家私营生物制药公司）担任多个业务开发职位。在Decode Genetics之前，McDermott先生是Agouron Pharmaceuticals，Inc.血管生成药理学小组的研究科学家。McDermott先生目前担任欧米茄基金（Omega Funds）的顾问，这是一家创建和投资生命科学公司的投资公司。McDermott先生拥有圣地亚哥大学（University of San Diego）的工商管理硕士学位，加州大学圣巴巴拉分校（University of California at Santa Barbara）的分子，细胞和发育生物学硕士学位，California University of Santa Cruz生物化学和分子生物学学士学位以及University of California San Diego Extension临床试验设计和管理证书。
- Charles McDermott has served as a member of our Board since September 2018. Mr. McDermott has served as Chairman, President and Chief Executive Officer of Primmune Therapeutics, Inc., a privately-held biotechnology company, since March 2019. From September 2017 to May 2018 Mr. McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately-held biotechnology company. Prior to that, Mr. McDermott served as President and Chief Business Officer of Kala Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from June 2015 to August 2017. Previously, he served as Interim President and Chief Business Officer of Kala from October 2014 to June 2015 and as Executive Vice President of Business Development of Kala from June 2013 to October 2014. Prior to joining Kala, Mr. McDermott served first as Director and then Vice President of Business Development, Eye Care and Drug Delivery at Allergan plc, a publicly-held global pharmaceutical company, where he worked from April 2005 to May 2013. Prior to joining Allergan, Mr. McDermott held a variety of business development positions at deCODE Genetics, Inc. now DGI Resolutions, Inc., a privately-held biopharmaceutical company, from January 2001 to March 2005. Prior to deCODE Genetics, Mr. McDermott was a research scientist in the angiogenesis pharmacology group at Agouron Pharmaceuticals, Inc. Mr. McDermott currently serves as an Advisor to Omega Funds, an investment firm that creates and invests in life sciences companies. Mr. McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension.
- Bala S. Manian
-
自2004年Reametrix Inc.（一家私营生物技术公司）成立以来，BalaS.Manian一直担任该公司董事会主席。他目前还担任Syngene International Limited的董事，这是一家公开交易的印度生物技术公司，此前曾担任Biocon Ltd.的董事，这是一家公开交易的印度生物制药公司。Manian博士是量子点公司（Quantum Dot Corporation）的联合创始人兼董事，这是一家私人持有的生物科学公司，也是SurroMed，Inc.（一家私人持有的生物技术公司）的联合创始人，并在其他生命科学公司担任董事。他也曾担任Lumisys Incorporated公司（医学影像公司，被Eastman Kodak Co.收购）的创始人兼董事会主席、Molecular Dynamics Incorporated公司（生命科学仪器公司，被ApBiotech Inc.收购）的创始人兼董事会主席，以及一家私人持有的生物技术公司-Biometric Imaging Inc.的创始人和董事会主席。Manian博士在马德拉斯大学（University of Madras）获得物理学学士学位，在罗切斯特大学（University of Rochester）获得应用光学硕士学位，在普渡大学（Purdue University）获得机械工程博士学位。
Bala S. Manian has served as chairman of the board of directors of ReaMetrix Inc., a privately held biotechnology company, since founding the company in 2004. He also currently serves as a director of Syngene International Limited, a publicly traded Indian biotechnology company, and previously served as a director of Biocon Ltd., a publicly traded Indian biopharmaceutical company. Dr. Manian is a co-founder and director of Quantum Dot Corporation, a privately held bioscience company, and a co-founder of SurroMed, Inc., a privately held biotechnology company, and serves as a director at other life sciences companies. He was also the founder and chairman of the board of directors of Lumisys Incorporated, a medical imaging company acquired by Eastman Kodak Co., the founder and chairman of the board of directors of Molecular Dynamics Incorporated, a life science instrumentation company acquired by APBiotech Inc., and the founder and chairman of the board of directors of Biometric Imaging Inc., a privately held biotechnology company. Dr. Manian received a B.S. in Physics from the University of Madras, an M.S. in Applied Optics from the University of Rochester and a Ph.D. in Mechanical Engineering from Purdue University. - 自2004年Reametrix Inc.（一家私营生物技术公司）成立以来，BalaS.Manian一直担任该公司董事会主席。他目前还担任Syngene International Limited的董事，这是一家公开交易的印度生物技术公司，此前曾担任Biocon Ltd.的董事，这是一家公开交易的印度生物制药公司。Manian博士是量子点公司（Quantum Dot Corporation）的联合创始人兼董事，这是一家私人持有的生物科学公司，也是SurroMed，Inc.（一家私人持有的生物技术公司）的联合创始人，并在其他生命科学公司担任董事。他也曾担任Lumisys Incorporated公司（医学影像公司，被Eastman Kodak Co.收购）的创始人兼董事会主席、Molecular Dynamics Incorporated公司（生命科学仪器公司，被ApBiotech Inc.收购）的创始人兼董事会主席，以及一家私人持有的生物技术公司-Biometric Imaging Inc.的创始人和董事会主席。Manian博士在马德拉斯大学（University of Madras）获得物理学学士学位，在罗切斯特大学（University of Rochester）获得应用光学硕士学位，在普渡大学（Purdue University）获得机械工程博士学位。
- Bala S. Manian has served as chairman of the board of directors of ReaMetrix Inc., a privately held biotechnology company, since founding the company in 2004. He also currently serves as a director of Syngene International Limited, a publicly traded Indian biotechnology company, and previously served as a director of Biocon Ltd., a publicly traded Indian biopharmaceutical company. Dr. Manian is a co-founder and director of Quantum Dot Corporation, a privately held bioscience company, and a co-founder of SurroMed, Inc., a privately held biotechnology company, and serves as a director at other life sciences companies. He was also the founder and chairman of the board of directors of Lumisys Incorporated, a medical imaging company acquired by Eastman Kodak Co., the founder and chairman of the board of directors of Molecular Dynamics Incorporated, a life science instrumentation company acquired by APBiotech Inc., and the founder and chairman of the board of directors of Biometric Imaging Inc., a privately held biotechnology company. Dr. Manian received a B.S. in Physics from the University of Madras, an M.S. in Applied Optics from the University of Rochester and a Ph.D. in Mechanical Engineering from Purdue University.
- Stephen Connelly
-
Stephen Connelly自2018年1月起担任首席科学官，自2017年3月起担任董事会成员。Connelly博士是Equillium的联合创始人，并于2017年3月至2018年1月担任顾问。Connelly博士自2016年3月起担任BioMed Ventures（BioMed Realty，LP拥有的投资公司）的负责人。2014年3月至2016年3月，Connelly博士担任上市生物技术公司aTyr制药公司的业务开发和治疗联盟总监。此前，他曾担任Scripps Research Institute的高级科学家（从2012年3月到2014年3月），在那里他曾从事多种药物发现项目，涉及不同的治疗领域。Connelly博士在进行新颖和创新研究方面有着丰富的经验，并发表了30多篇原创科学论文和专利。Connelly博士在英国埃克塞特大学（University of Exeter，United Kingdom）获得药物化学学士学位和生物化学博士学位，并在圣地亚哥加利福尼亚大学（University of California）的雷迪学院（Rady School）获得工商管理硕士学位。
Stephen Connelly has served as our Chief Scientific Officer since January 2018 and as a member of our Board since March 2017. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016 Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014 where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego. - Stephen Connelly自2018年1月起担任首席科学官，自2017年3月起担任董事会成员。Connelly博士是Equillium的联合创始人，并于2017年3月至2018年1月担任顾问。Connelly博士自2016年3月起担任BioMed Ventures（BioMed Realty，LP拥有的投资公司）的负责人。2014年3月至2016年3月，Connelly博士担任上市生物技术公司aTyr制药公司的业务开发和治疗联盟总监。此前，他曾担任Scripps Research Institute的高级科学家（从2012年3月到2014年3月），在那里他曾从事多种药物发现项目，涉及不同的治疗领域。Connelly博士在进行新颖和创新研究方面有着丰富的经验，并发表了30多篇原创科学论文和专利。Connelly博士在英国埃克塞特大学（University of Exeter，United Kingdom）获得药物化学学士学位和生物化学博士学位，并在圣地亚哥加利福尼亚大学（University of California）的雷迪学院（Rady School）获得工商管理硕士学位。
- Stephen Connelly has served as our Chief Scientific Officer since January 2018 and as a member of our Board since March 2017. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016 Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014 where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.
- Mark Pruzanski
-
暂无中文简介
Mark Pruzanski has served as a member of our Board since September 2018. Dr. Pruzanski is a co-founder and has served as President and Chief Executive Officer and as a member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, since 2002. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Prior to co-founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co-author of a number of scientific publications and is named as an inventor on several patents. Dr. Pruzanski currently serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization, a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor’s degree from McGill University in Montreal, Canada. -
暂无中文简介
- Mark Pruzanski has served as a member of our Board since September 2018. Dr. Pruzanski is a co-founder and has served as President and Chief Executive Officer and as a member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, since 2002. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Prior to co-founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co-author of a number of scientific publications and is named as an inventor on several patents. Dr. Pruzanski currently serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization, a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor’s degree from McGill University in Montreal, Canada.
- Daniel M. Bradbury
-
Daniel M. Bradbury，2007年3月起，担任本公司的首席执行官；2006年6月起，担任总裁；2003年6月起，担任首席运营官。他从2006年6月起，担任董事，现为财务委员会成员。之前，2000年6月至2003年6月，他曾担任执行副总裁。他于1994年加入Amylin，担任过企业发展与营销方面多个主管级别的职务。加入Amylin之前，他在SmithKline Beecham Pharmaceuticals工作了10年，担任过销售和营销方面的多个职务。他目前是Illumina的董事、RAND Health的顾问委员会成员，以及PhRMA、BIOCOM的委员会成员，还是Keck Graduate Institute、San Diego Regional Economic Development Corporation的董事。他还任职于UCSD Rady School of Manment’s Advisory Council、University of Miami’s Innovation Corporate Advisory Council 、University of Miami’s Diabetes Research Institute Corporate Advisory Council。他在Nottingham University获得药理学士学位，在Harrow and Ealing Colleges of Higher Education获得管理研究文凭。
Daniel M. Bradbury has served as Equillium, Inc. Executive Chairman of our Board since January 2020 and has been a member and the chairman of our Board since March 2017. He served as our Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as our President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC, or BioBrit, a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals, a privately-held pharmaceutical company. Mr. Bradbury serves on the board of directors of numerous private companies and the following publicly-held companies: Castle Biosciences, and Intercept Pharmaceuticals, Inc. Mr. Bradbury previously served on the board of directors of BioMed Realty Trust, Inc., a publicly-held real estate investment trust company, from 2013 to 2016; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Syngene International Ltd., a publicly-held science research company, from 2015 to 2016. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. - Daniel M. Bradbury，2007年3月起，担任本公司的首席执行官；2006年6月起，担任总裁；2003年6月起，担任首席运营官。他从2006年6月起，担任董事，现为财务委员会成员。之前，2000年6月至2003年6月，他曾担任执行副总裁。他于1994年加入Amylin，担任过企业发展与营销方面多个主管级别的职务。加入Amylin之前，他在SmithKline Beecham Pharmaceuticals工作了10年，担任过销售和营销方面的多个职务。他目前是Illumina的董事、RAND Health的顾问委员会成员，以及PhRMA、BIOCOM的委员会成员，还是Keck Graduate Institute、San Diego Regional Economic Development Corporation的董事。他还任职于UCSD Rady School of Manment’s Advisory Council、University of Miami’s Innovation Corporate Advisory Council 、University of Miami’s Diabetes Research Institute Corporate Advisory Council。他在Nottingham University获得药理学士学位，在Harrow and Ealing Colleges of Higher Education获得管理研究文凭。
- Daniel M. Bradbury has served as Equillium, Inc. Executive Chairman of our Board since January 2020 and has been a member and the chairman of our Board since March 2017. He served as our Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as our President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC, or BioBrit, a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals, a privately-held pharmaceutical company. Mr. Bradbury serves on the board of directors of numerous private companies and the following publicly-held companies: Castle Biosciences, and Intercept Pharmaceuticals, Inc. Mr. Bradbury previously served on the board of directors of BioMed Realty Trust, Inc., a publicly-held real estate investment trust company, from 2013 to 2016; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Syngene International Ltd., a publicly-held science research company, from 2015 to 2016. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
- Mark Pruzanski
-
Mark Pruzanski，医学博士，是Intercept Pharmaceuticals, Inc.的联合成立者，自2002年公司成立以来担任Intercept Pharmaceuticals, Inc.的首席执行官和总裁，以及公司董事。他有着超过15年的生命科学公司管理、风险资本和战略咨询方面的经验。Pruzanski博士早前曾是Apple Tree Partners（他于1999年联合成立的早期阶段生命科学风险资本企业）的风险投资合伙人。在那之前，他曾是Oak Investment Partners的常驻企业家。Pruzanski博士获得了安大略McMaster University的医学博士学位， 意大利博洛尼亚和华盛顿特区the Johns Hopkins University School of Advanced International Studies的国际事务硕士学位，魁北克蒙特利尔McGill University的学士学位。他目前担任 Emerging Company Section of the Biotechnology Industry Association BIO 和 the Foundation for the Defense of Democracies（华盛顿特区的一个智库）的董事。Pruzanski博士是大量科学出版物的合著人，以及关于候选人和科学发现的几项专利的发明人。
Mark Pruzanski, M.D. is a co-founder of Intercept Pharmaceuticals, Inc. company and has served as our chief executive officer and president, and has been a member of our board of directors, since our inception in 2002. He has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Dr. Pruzanski was previously a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm he co-founded in 1999. Prior to that, he was an entrepreneur-in-residence at Oak Investment Partners. Dr. Pruzanski received his M.D. from McMaster University in Ontario, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor's degree from McGill University in Montreal, Quebec. He currently also serves on the boards of the Emerging Company Section of the Biotechnology Industry Association BIO and the Foundation for the Defense of Democracies, a think tank in Washington, D.C. Dr. Pruzanski is a co-author of a number of scientific publications and an inventor of several patents relating to our product candidates and scientific discoveries. - Mark Pruzanski，医学博士，是Intercept Pharmaceuticals, Inc.的联合成立者，自2002年公司成立以来担任Intercept Pharmaceuticals, Inc.的首席执行官和总裁，以及公司董事。他有着超过15年的生命科学公司管理、风险资本和战略咨询方面的经验。Pruzanski博士早前曾是Apple Tree Partners（他于1999年联合成立的早期阶段生命科学风险资本企业）的风险投资合伙人。在那之前，他曾是Oak Investment Partners的常驻企业家。Pruzanski博士获得了安大略McMaster University的医学博士学位， 意大利博洛尼亚和华盛顿特区the Johns Hopkins University School of Advanced International Studies的国际事务硕士学位，魁北克蒙特利尔McGill University的学士学位。他目前担任 Emerging Company Section of the Biotechnology Industry Association BIO 和 the Foundation for the Defense of Democracies（华盛顿特区的一个智库）的董事。Pruzanski博士是大量科学出版物的合著人，以及关于候选人和科学发现的几项专利的发明人。
- Mark Pruzanski, M.D. is a co-founder of Intercept Pharmaceuticals, Inc. company and has served as our chief executive officer and president, and has been a member of our board of directors, since our inception in 2002. He has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Dr. Pruzanski was previously a venture partner at Apple Tree Partners, an early stage life sciences venture capital firm he co-founded in 1999. Prior to that, he was an entrepreneur-in-residence at Oak Investment Partners. Dr. Pruzanski received his M.D. from McMaster University in Ontario, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor's degree from McGill University in Montreal, Quebec. He currently also serves on the boards of the Emerging Company Section of the Biotechnology Industry Association BIO and the Foundation for the Defense of Democracies, a think tank in Washington, D.C. Dr. Pruzanski is a co-author of a number of scientific publications and an inventor of several patents relating to our product candidates and scientific discoveries.
- Martha J. Demski
-
自2005年以来Martha J. Demski一直担任Equillium, Inc.的董事之一。自2011年8月以来她曾担任 Ajinimoto Althea, Inc. formerly Althea Technologies, Inc（全面集成的开发和生产组织）的高级副总裁兼首席财务官。从2008年7月到2010年12月她担任idney Kimmel Cancer Center （SKCC）（一个从事生物医学研究在2009年自愿申请破产非盈利的公司）的临时首席运营官和首席财务官。2006年4月至2008年5月担任U.S. Trust的高级副总裁。从2005年到2008年7月就职于Trustees at SKCC董事，审计委员会主席以及管理和提名委员会主席。从1988年12月到2004年6月担任Vical Incorporated（一家生物制药公司）副总裁、首席财务官、财务主管兼总监。她也担任Adamas Pharmaceuticals, Inc董事和审计委员会主席。她在密歇根州立大学获得了B.A.学士学位和芝加哥大学布斯商学院M.B.A. 学位。
Martha J. Demski has served as a member of our Board since September 2018. From August 2011 to May 2017 Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc., now known as Ajinmoto Bio-Pharma Services, a privately-held fully-integrated contract development and manufacturing organization. From July 2008 to December 2010 Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center, a non-profit corporation that was engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a publicly-held biopharmaceutical company, from December 1989 to June 2004. Ms. Demski currently serves as the chair of the board of directors of Chimerix, Inc., a publicly-held biopharmaceutical company, and on the board of directors, as the chair of the audit committee and as a member of the compensation committee, of Adamas Pharmaceuticals, Inc., a publicly-held biotechnology company. Prior to 2018 Ms. Demski was a member of the board of directors, chair of the audit committee and member of the compensation committee, nominating and governance committee, and operating committee of Neothetics, Inc., a publicly-held biotechnology company that merged with Evofem Biosciences, Inc. in 2018. Ms. Demski is a National Association of Corporate Directors Board Governance Fellow. In 2017 she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America. Ms. Demski earned a B.A. from Michigan State University and an M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance. - 自2005年以来Martha J. Demski一直担任Equillium, Inc.的董事之一。自2011年8月以来她曾担任 Ajinimoto Althea, Inc. formerly Althea Technologies, Inc（全面集成的开发和生产组织）的高级副总裁兼首席财务官。从2008年7月到2010年12月她担任idney Kimmel Cancer Center （SKCC）（一个从事生物医学研究在2009年自愿申请破产非盈利的公司）的临时首席运营官和首席财务官。2006年4月至2008年5月担任U.S. Trust的高级副总裁。从2005年到2008年7月就职于Trustees at SKCC董事，审计委员会主席以及管理和提名委员会主席。从1988年12月到2004年6月担任Vical Incorporated（一家生物制药公司）副总裁、首席财务官、财务主管兼总监。她也担任Adamas Pharmaceuticals, Inc董事和审计委员会主席。她在密歇根州立大学获得了B.A.学士学位和芝加哥大学布斯商学院M.B.A. 学位。
- Martha J. Demski has served as a member of our Board since September 2018. From August 2011 to May 2017 Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc., now known as Ajinmoto Bio-Pharma Services, a privately-held fully-integrated contract development and manufacturing organization. From July 2008 to December 2010 Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center, a non-profit corporation that was engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a publicly-held biopharmaceutical company, from December 1989 to June 2004. Ms. Demski currently serves as the chair of the board of directors of Chimerix, Inc., a publicly-held biopharmaceutical company, and on the board of directors, as the chair of the audit committee and as a member of the compensation committee, of Adamas Pharmaceuticals, Inc., a publicly-held biotechnology company. Prior to 2018 Ms. Demski was a member of the board of directors, chair of the audit committee and member of the compensation committee, nominating and governance committee, and operating committee of Neothetics, Inc., a publicly-held biotechnology company that merged with Evofem Biosciences, Inc. in 2018. Ms. Demski is a National Association of Corporate Directors Board Governance Fellow. In 2017 she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America. Ms. Demski earned a B.A. from Michigan State University and an M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance.
- Bruce D. Steel
-
BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
Bruce D. Steel has served as our President and Chief Executive Officer since January 2020 and as a member of our Board since March 2017. He served as our President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co-founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010 Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was co-founder and Chief Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr. Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from 2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst. - BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
- Bruce D. Steel has served as our President and Chief Executive Officer since January 2020 and as a member of our Board since March 2017. He served as our President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co-founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010 Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was co-founder and Chief Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr. Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from 2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.
高管简历
中英对照 | 中文 | 英文- Jason A. Keyes
JasonA.Keyes自2020年2月起担任董事会成员。凯斯先生曾担任Equillium，Inc.的首席财务官。纳斯达克股票代码:EQ自2018年3月以来。在加入Equillium之前，他于2016年6月至2018年2月担任OrexigenTherapeutics，Inc.执行Vice President兼首席财务官，在为产品组合的全球商业化制定业务和财务战略方面发挥了关键作用。在担任首席财务官之前，凯斯先生于2015年2月至2016年6月担任Orexigen财务Vice President。在此之前，2007年8月至2013年1月，凯斯先生在AmylinPharmaceuticals，Inc.公司（一家上市生物制药公司）担任越来越重要的职务。在其职业生涯早期，凯斯先生曾在Amgen，Inc.（一家上市生物制药公司）和Baxter梦百合Corporation（一家上市梦百合公司）担任财务和公司战略领导职务。在他的职业生涯中，Keyes先生一直负责领导整个生物技术价值链的财务规划，管理投资者关系，筹集资金并推动业务发展。
Jason A. Keyes has served as a member of our Board since February 2020. Mr. Keyes has served as the Chief Financial Officer of Equillium, Inc. Nasdaq: EQ since March 2018. Prior to joining Equillium, he was Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc. from June 2016 to February 2018 where he played a key role in setting the business and financial strategy for the global commercialization of the product portfolio. Prior to his role as Chief Financial Officer, Mr. Keyes, held the position of Vice President, Finance at Orexigen from February 2015 to June 2016. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Before that, Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013. Earlier in his career, Mr. Keyes held leadership positions in finance and corporate strategy at Amgen, Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Over his career, Mr. Keyes has been responsible for leading financial planning across the biotechnology value chain, managing investor relations, raising capital, and driving business development.- JasonA.Keyes自2020年2月起担任董事会成员。凯斯先生曾担任Equillium，Inc.的首席财务官。纳斯达克股票代码:EQ自2018年3月以来。在加入Equillium之前，他于2016年6月至2018年2月担任OrexigenTherapeutics，Inc.执行Vice President兼首席财务官，在为产品组合的全球商业化制定业务和财务战略方面发挥了关键作用。在担任首席财务官之前，凯斯先生于2015年2月至2016年6月担任Orexigen财务Vice President。在此之前，2007年8月至2013年1月，凯斯先生在AmylinPharmaceuticals，Inc.公司（一家上市生物制药公司）担任越来越重要的职务。在其职业生涯早期，凯斯先生曾在Amgen，Inc.（一家上市生物制药公司）和Baxter梦百合Corporation（一家上市梦百合公司）担任财务和公司战略领导职务。在他的职业生涯中，Keyes先生一直负责领导整个生物技术价值链的财务规划，管理投资者关系，筹集资金并推动业务发展。
- Jason A. Keyes has served as a member of our Board since February 2020. Mr. Keyes has served as the Chief Financial Officer of Equillium, Inc. Nasdaq: EQ since March 2018. Prior to joining Equillium, he was Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc. from June 2016 to February 2018 where he played a key role in setting the business and financial strategy for the global commercialization of the product portfolio. Prior to his role as Chief Financial Officer, Mr. Keyes, held the position of Vice President, Finance at Orexigen from February 2015 to June 2016. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Before that, Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013. Earlier in his career, Mr. Keyes held leadership positions in finance and corporate strategy at Amgen, Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Over his career, Mr. Keyes has been responsible for leading financial planning across the biotechnology value chain, managing investor relations, raising capital, and driving business development.
- Stephen Connelly
Stephen Connelly自2018年1月起担任首席科学官，自2017年3月起担任董事会成员。Connelly博士是Equillium的联合创始人，并于2017年3月至2018年1月担任顾问。Connelly博士自2016年3月起担任BioMed Ventures（BioMed Realty，LP拥有的投资公司）的负责人。2014年3月至2016年3月，Connelly博士担任上市生物技术公司aTyr制药公司的业务开发和治疗联盟总监。此前，他曾担任Scripps Research Institute的高级科学家（从2012年3月到2014年3月），在那里他曾从事多种药物发现项目，涉及不同的治疗领域。Connelly博士在进行新颖和创新研究方面有着丰富的经验，并发表了30多篇原创科学论文和专利。Connelly博士在英国埃克塞特大学（University of Exeter，United Kingdom）获得药物化学学士学位和生物化学博士学位，并在圣地亚哥加利福尼亚大学（University of California）的雷迪学院（Rady School）获得工商管理硕士学位。
Stephen Connelly has served as our Chief Scientific Officer since January 2018 and as a member of our Board since March 2017. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016 Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014 where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.- Stephen Connelly自2018年1月起担任首席科学官，自2017年3月起担任董事会成员。Connelly博士是Equillium的联合创始人，并于2017年3月至2018年1月担任顾问。Connelly博士自2016年3月起担任BioMed Ventures（BioMed Realty，LP拥有的投资公司）的负责人。2014年3月至2016年3月，Connelly博士担任上市生物技术公司aTyr制药公司的业务开发和治疗联盟总监。此前，他曾担任Scripps Research Institute的高级科学家（从2012年3月到2014年3月），在那里他曾从事多种药物发现项目，涉及不同的治疗领域。Connelly博士在进行新颖和创新研究方面有着丰富的经验，并发表了30多篇原创科学论文和专利。Connelly博士在英国埃克塞特大学（University of Exeter，United Kingdom）获得药物化学学士学位和生物化学博士学位，并在圣地亚哥加利福尼亚大学（University of California）的雷迪学院（Rady School）获得工商管理硕士学位。
- Stephen Connelly has served as our Chief Scientific Officer since January 2018 and as a member of our Board since March 2017. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016 Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014 where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.
- Krishna R. Polu
- 暂无中文简介
Krishna R. Polu has served as our Executive Vice President, Research and Development since January 2020. Dr. Polu served as our Chief Medical Officer from August 2018 through December 2019. From February 2018 to August 2018 Dr. Polu served as Interim Chief Executive Officer of Scout Bio, Inc., a privately-held biotechnology company. Dr. Polu founded Expedition Therapeutics, Inc., a privately-held search company, in June 2017 and served as its Chief Executive Officer from June 2017 until August 2018. Dr. Polu also served as an Entrepreneur-in-Residence at Frazier Healthcare Partners, an investment firm, from February 2017 until August 2018. Prior to that, Dr. Polu served as the Chief Medical Officer of Raptor Pharmaceutical Corp., a publicly-held biopharmaceutical company, from January 2015 to December 2016. Dr. Polu also previously served as the Chief Medical Officer of CytomX Therapeutics, Inc., a privately-held biotechnology company, from March 2013 to June 2014. From July 2009 to March 2013 Dr. Polu served as Vice President of Clinical Development at Affymax, Inc., a publicly-held biopharmaceutical company. Prior to Affymax, Inc., Dr. Polu served as the Executive Director, Global Development of Amgen Inc., a publicly-held biotechnology company, from November 2007 to July 2009. Dr. Polu holds a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science Center, San Antonio. Dr. Polu also completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women’s Hospital and Massachusetts General Hospital. - 暂无中文简介
- Krishna R. Polu has served as our Executive Vice President, Research and Development since January 2020. Dr. Polu served as our Chief Medical Officer from August 2018 through December 2019. From February 2018 to August 2018 Dr. Polu served as Interim Chief Executive Officer of Scout Bio, Inc., a privately-held biotechnology company. Dr. Polu founded Expedition Therapeutics, Inc., a privately-held search company, in June 2017 and served as its Chief Executive Officer from June 2017 until August 2018. Dr. Polu also served as an Entrepreneur-in-Residence at Frazier Healthcare Partners, an investment firm, from February 2017 until August 2018. Prior to that, Dr. Polu served as the Chief Medical Officer of Raptor Pharmaceutical Corp., a publicly-held biopharmaceutical company, from January 2015 to December 2016. Dr. Polu also previously served as the Chief Medical Officer of CytomX Therapeutics, Inc., a privately-held biotechnology company, from March 2013 to June 2014. From July 2009 to March 2013 Dr. Polu served as Vice President of Clinical Development at Affymax, Inc., a publicly-held biopharmaceutical company. Prior to Affymax, Inc., Dr. Polu served as the Executive Director, Global Development of Amgen Inc., a publicly-held biotechnology company, from November 2007 to July 2009. Dr. Polu holds a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science Center, San Antonio. Dr. Polu also completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women’s Hospital and Massachusetts General Hospital.
- Christine Zedelmayer
Christine Zedelmayer自2020年1月起担任高级副总裁，首席运营官。Zedelmayer女士于2018年2月至2019年12月担任我们的运营Vice President。在加入Equillium之前，Zedelmayer女士是Centerra Consulting，LLC的所有者兼首席顾问，该公司是一家专注于生命科学的项目管理和投资者关系咨询公司，2012年至2018年2月，她领导客户的战略业务发展项目，并担任多家医疗器械公司的投资者关系主管。在加入Centerra之前，Zedelmayer女士从2003年到2012年在上市生物制药公司AmylinPharmaceuticals，Inc.担任过各种职务，包括联盟管理高级总监，在那里她领导了与礼来公司的全球合作，并担任投资者关系执行总监。在加入Amylin之前，Zedelmayer女士在上市生物制药公司安进公司、上市生物制药公司Ligand Pharmaceuticals，Inc.和私营医疗诊断公司Hybritech，Inc.担任过多个项目管理方面的领导职务。Zedelmayer女士在圣地亚哥州立大学（San Diego State University）获得电气工程学士学位，并在加州路德大学（California Lutheran University）获得工商管理硕士学位，重点是财务。
Christine Zedelmayer has served as Senior Vice President, Chief Operating Officer since January 2020. Ms. Zedelmayer served as our Vice President of Operations from February 2018 through December 2019. Prior to Equillium, Ms. Zedelmayer was owner and principal consultant at Centerra Consulting, LLC, a project management and investor relations consulting firm focused on life sciences, from 2012 to February 2018 where she led strategic business development projects for clients and served as head of investor relations for a variety of medical device companies. Prior to Centerra, from 2003 to 2012 Ms. Zedelmayer held a variety of roles at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, including Senior Director of Alliance Management, where she led the global collaboration with Eli Lilly and as Executive Director of Investor Relations. Before joining Amylin, Ms. Zedelmayer held various leadership positions within project management at Amgen Inc., a publicly-held biopharmaceutical company, Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, and Hybritech, Inc., a privately-held medical diagnostics company. Ms. Zedelmayer received her B.S. in Electrical Engineering at San Diego State University and a M.B.A. with Finance emphasis at California Lutheran University.- Christine Zedelmayer自2020年1月起担任高级副总裁，首席运营官。Zedelmayer女士于2018年2月至2019年12月担任我们的运营Vice President。在加入Equillium之前，Zedelmayer女士是Centerra Consulting，LLC的所有者兼首席顾问，该公司是一家专注于生命科学的项目管理和投资者关系咨询公司，2012年至2018年2月，她领导客户的战略业务发展项目，并担任多家医疗器械公司的投资者关系主管。在加入Centerra之前，Zedelmayer女士从2003年到2012年在上市生物制药公司AmylinPharmaceuticals，Inc.担任过各种职务，包括联盟管理高级总监，在那里她领导了与礼来公司的全球合作，并担任投资者关系执行总监。在加入Amylin之前，Zedelmayer女士在上市生物制药公司安进公司、上市生物制药公司Ligand Pharmaceuticals，Inc.和私营医疗诊断公司Hybritech，Inc.担任过多个项目管理方面的领导职务。Zedelmayer女士在圣地亚哥州立大学（San Diego State University）获得电气工程学士学位，并在加州路德大学（California Lutheran University）获得工商管理硕士学位，重点是财务。
- Christine Zedelmayer has served as Senior Vice President, Chief Operating Officer since January 2020. Ms. Zedelmayer served as our Vice President of Operations from February 2018 through December 2019. Prior to Equillium, Ms. Zedelmayer was owner and principal consultant at Centerra Consulting, LLC, a project management and investor relations consulting firm focused on life sciences, from 2012 to February 2018 where she led strategic business development projects for clients and served as head of investor relations for a variety of medical device companies. Prior to Centerra, from 2003 to 2012 Ms. Zedelmayer held a variety of roles at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, including Senior Director of Alliance Management, where she led the global collaboration with Eli Lilly and as Executive Director of Investor Relations. Before joining Amylin, Ms. Zedelmayer held various leadership positions within project management at Amgen Inc., a publicly-held biopharmaceutical company, Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, and Hybritech, Inc., a privately-held medical diagnostics company. Ms. Zedelmayer received her B.S. in Electrical Engineering at San Diego State University and a M.B.A. with Finance emphasis at California Lutheran University.
- Krishna R. Polu
Krishna R. Polu，他于2015年1月12日被任命为我们的首席医疗官。他最近曾担任CytomX Therapeutics公司（一个私营生物技术公司）的首席医疗官（从2013年3月到2014年6月）。从2009年7月到2013年3月，他担任Affymax公司的副总裁，负责临床开发。任职Affymax公司之前，他曾担任Amgen公司的执行董事，负责全球开发（2005年10月至2009年7月）。他持有Stanford University的学士学位，以及德克萨斯大学圣安东尼奥分校（the University of Texas, San Antonio）的医学博士学位。他完成了the University of Colorado的内科医学实习、驻院实习，以及肾脏学和移植的临床和研究奖学金，涉及哈佛医学院（Harvard Medical School）与布莱根妇女医院（Brigham and Women’s Hospital）和马萨诸塞州总医院（Massachusetts General Hospital）的合作项目。
Krishna R. Polu M.D., serves on board of directors. Since January 2021 Dr. Polu has served as a principal at Red Tree Venture Capital. Dr. Polu previously served as the Executive Vice President R&D of Equillium, Inc. NASDAQ: EQ from January 2020 to December 2020 and additionally served as Chief Medical Officer from August 2018 to December 2020. Since January 2021 Dr. Polu has served as a principal at Red Tree Venture Capital. Dr. Polu also serves as a member of the board of directors of Goldilocks Therapeutics, where he previously served as a strategic advisor from February 2018 to January 2020. Prior to that, Dr. Polu was an Entrepreneur in Residence at Frazier from February 2017 to August 2018 where he founded Expedition Therapeutics, a search company focused on identifying and in-licensing assets in the kidney and autoimmune therapeutic areas. During this time, he also served as interim Chief Executive Officer of Scout Bio, a company focused on the discovery and development of gene therapies for companion animals. From January 2015 to December 2016 Dr. Polu served as Chief Medical Officer at Raptor Pharmaceuticals, a then-public company focused on rare diseases, until its acquisition by Horizon Pharmaceuticals for $800 million. In that role, he oversaw clinical development, regulatory affairs, pharmacovigilance and medical affairs, and was responsible for securing additional drug approvals for Procysbi in nephropathic cystinosis, supporting product launches for Quinsair in cystic fibrosis, and advancing the pipeline in other rare diseases including Huntington’s disease, cystic fibrosis, bronchiectasis and nontuberculous mycobacteria. Prior to Raptor, Dr. Polu served as Chief Medical Officer at CytomX Therapeutics (NASDAQ: CTMX) and directed preclinical development and translational research efforts for the Probody platform in oncology and helped secure a number of Pharma partnerships. Prior to CytomX, he led clinical development and pharmacovigilance activities at Affymax, a then-public biopharmaceutical company, where he was instrumental in securing FDA approval of peginesatide for the treatment of anemia in patients on dialysis. Dr. Polu also held senior level positions in clinical development at Amgen (NASDAQ: AMGN) and was responsible for leading clinical development programs in heart failure, anemia of chronic kidney disease, and diabetes.- Krishna R. Polu，他于2015年1月12日被任命为我们的首席医疗官。他最近曾担任CytomX Therapeutics公司（一个私营生物技术公司）的首席医疗官（从2013年3月到2014年6月）。从2009年7月到2013年3月，他担任Affymax公司的副总裁，负责临床开发。任职Affymax公司之前，他曾担任Amgen公司的执行董事，负责全球开发（2005年10月至2009年7月）。他持有Stanford University的学士学位，以及德克萨斯大学圣安东尼奥分校（the University of Texas, San Antonio）的医学博士学位。他完成了the University of Colorado的内科医学实习、驻院实习，以及肾脏学和移植的临床和研究奖学金，涉及哈佛医学院（Harvard Medical School）与布莱根妇女医院（Brigham and Women’s Hospital）和马萨诸塞州总医院（Massachusetts General Hospital）的合作项目。
- Krishna R. Polu M.D., serves on board of directors. Since January 2021 Dr. Polu has served as a principal at Red Tree Venture Capital. Dr. Polu previously served as the Executive Vice President R&D of Equillium, Inc. NASDAQ: EQ from January 2020 to December 2020 and additionally served as Chief Medical Officer from August 2018 to December 2020. Since January 2021 Dr. Polu has served as a principal at Red Tree Venture Capital. Dr. Polu also serves as a member of the board of directors of Goldilocks Therapeutics, where he previously served as a strategic advisor from February 2018 to January 2020. Prior to that, Dr. Polu was an Entrepreneur in Residence at Frazier from February 2017 to August 2018 where he founded Expedition Therapeutics, a search company focused on identifying and in-licensing assets in the kidney and autoimmune therapeutic areas. During this time, he also served as interim Chief Executive Officer of Scout Bio, a company focused on the discovery and development of gene therapies for companion animals. From January 2015 to December 2016 Dr. Polu served as Chief Medical Officer at Raptor Pharmaceuticals, a then-public company focused on rare diseases, until its acquisition by Horizon Pharmaceuticals for $800 million. In that role, he oversaw clinical development, regulatory affairs, pharmacovigilance and medical affairs, and was responsible for securing additional drug approvals for Procysbi in nephropathic cystinosis, supporting product launches for Quinsair in cystic fibrosis, and advancing the pipeline in other rare diseases including Huntington’s disease, cystic fibrosis, bronchiectasis and nontuberculous mycobacteria. Prior to Raptor, Dr. Polu served as Chief Medical Officer at CytomX Therapeutics (NASDAQ: CTMX) and directed preclinical development and translational research efforts for the Probody platform in oncology and helped secure a number of Pharma partnerships. Prior to CytomX, he led clinical development and pharmacovigilance activities at Affymax, a then-public biopharmaceutical company, where he was instrumental in securing FDA approval of peginesatide for the treatment of anemia in patients on dialysis. Dr. Polu also held senior level positions in clinical development at Amgen (NASDAQ: AMGN) and was responsible for leading clinical development programs in heart failure, anemia of chronic kidney disease, and diabetes.
- Bruce D. Steel
BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
Bruce D. Steel has served as our President and Chief Executive Officer since January 2020 and as a member of our Board since March 2017. He served as our President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co-founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010 Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was co-founder and Chief Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr. Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from 2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.- BruceD.Steel自2020年1月起担任公司总裁兼首席执行官，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任我们的总裁兼首席商务官。Steel先生是Equillium的联合创始人。Steel自2010年起担任BioMed Ventures（BioMed Realty，LP所有的投资公司）创始人和董事总经理。Steel从2008年到2010年担任Anaphore，Inc.（一家私人制药公司）首席商务官。在此之前，Steel从2005年到2008年担任Rincon Pharmaceuticals，Inc.（一家基因工程生物技术公司）联合创始人和首席执行官。Steel先生从2002年到2005年还担任过Ambit Biosciences Corporation公司的企业发展主管。Steel先生曾于2012年至2017年担任上市生物制药公司Zosano Pharma Corporation的董事会成员。Steel先生在达特茅斯学院（Dartmouth College）获得学士学位，在南加州大学马歇尔商学院（Marshall School of Business at the University of Southern California）获得工商管理硕士学位，他持有特许金融分析师的称号。
- Bruce D. Steel has served as our President and Chief Executive Officer since January 2020 and as a member of our Board since March 2017. He served as our President and Chief Business Officer from June 2018 through December 2019. Mr. Steel is a co-founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010 Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was co-founder and Chief Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr. Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from 2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.